The Huffington Post -
14 Dec 2013 01:44

Co-authored with Barbara Prainsack of the Department of Social Science, Health and Medicine, King's College London, UK Recent action by the FDA against the California-based personal genomics company 23andMe has sparked international attention and bemusement. While some observers agree with the FDA's insistence that the company stop marketing their tests until they have comprehensively backed up the validity of their health claims, to others, particularly outside the U.S., these developments seem...
Share this Article
Comment on this Article
Please to comment